Quick answer
Extended answer
How do Semaglutide and Tirzepatide compare?
Key facts
- Semaglutide class
- Selective GLP-1R agonist
- Tirzepatide class
- Dual GLP-1R / GIPR agonist
- Half-life (both)
- ≈ 5–7 days (SC, once-weekly)
- Head-to-head evidence
- SURPASS-2 (T2D, published 2021)
- Approved status (UK)
- Both approved (Semaglutide, Tirzepatide) via MHRA
Scientific overview
Semaglutide is a modified GLP-1 analogue described in 2015 as a once-weekly selective GLP-1R agonist.[1] Tirzepatide (LY3298176) is a dual GLP-1R / GIPR agonist engineered from the GIP backbone with substitutions that confer GLP-1R activity, and evaluated in head-to-head trials against Semaglutide in type 2 diabetes.[7]
Mechanism comparison
Both compounds engage Gαs → cAMP signalling at their respective receptors. Semaglutide activates GLP-1R only. Tirzepatide engages GLP-1R and GIPR, with reported partial biased signalling — full efficacy at GIPR, sub-maximal β-arrestin recruitment at GLP-1R in some reports. Downstream effects (insulinotropic, gastric emptying, central appetite) overlap but relative contributions differ.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Compound class | Selective GLP-1R agonist | Dual GLP-1R / GIPR agonist |
| Primary receptors | GLP-1R | GLP-1R + GIPR |
| Backbone | Modified GLP-1(7-37) | Modified GIP backbone |
| Fatty-acid modification | C18 di-acid at Lys26 (γGlu-2xOEG spacer) | C20 di-acid at Lys20 |
| DPP-4-resistant substitution | Aib8 | Aib2 + Aib13 |
| Second messenger | cAMP (Gαs) | cAMP (Gαs) at both receptors |
| Reported bias | Balanced G-protein / arrestin at GLP-1R | Partial arrestin bias reported at GLP-1R |
Receptor selectivity
Semaglutide is selective at GLP-1R with no meaningful GIPR or GCGR activity at pharmacologically relevant concentrations. Tirzepatide engages GLP-1R and GIPR from a single molecule; it does not activate GCGR at pharmacologically meaningful concentrations, distinguishing it from triple agonists such as Retatrutide.
Pharmacokinetic comparison
| Parameter | Semaglutide | Tirzepatide |
|---|---|---|
| Plasma half-life (human, SC) | ≈ 1 week | ≈ 5 days |
| Route | SC once-weekly; oral once-daily (with SNAC) | SC once-weekly |
| Albumin binding | > 99% (C18 di-acid) | > 99% (C20 di-acid) |
| Steady state (SC) | ≈ 4–5 weeks | ≈ 4 weeks |
| Clearance | Proteolysis; renal/faecal metabolite excretion | Proteolysis |
Research applications comparison
| Research area | Semaglutide | Tirzepatide |
|---|---|---|
| Type 2 diabetes | Landmark RCTs (SUSTAIN-6) | Landmark RCTs (SURPASS programme) |
| Obesity | STEP programme | SURMOUNT programme |
| Cardiovascular outcomes | SUSTAIN-6, SELECT | SURPASS-CVOT (data emerging) |
| Renal outcomes | FLOW | Under investigation |
| MASH / hepatic | Imaging + biopsy studies | Phase 2 signals |
| Head-to-head | vs Tirzepatide (SURPASS-2) | vs Semaglutide (SURPASS-2) |
Human evidence
SURPASS-2 compared once-weekly Tirzepatide (5, 10, 15 mg) with once-weekly Semaglutide 1 mg in adults with type 2 diabetes and reported greater HbA1c and body-weight reduction with Tirzepatide across all three doses.[7] SURMOUNT-1 reported obesity outcomes for Tirzepatide;[8] STEP-1 reported obesity outcomes for Semaglutide.[5]
Preclinical evidence
Preclinical characterisation of both compounds established receptor engagement, cAMP signalling and in-vivo metabolic effects. Reported in-vitro potencies differ across assays and are sensitive to albumin content — comparative claims require matched assay conditions.
Advantages and limitations
- Semaglutide — advantages: largest human evidence base including cardiovascular and renal outcomes; oral and subcutaneous formulations.
- Semaglutide — limitations: mono-agonism may deliver less efficacy on HbA1c and weight than dual/triple agonists in head-to-head trials.
- Tirzepatide — advantages: greater HbA1c and body-weight reduction in published head-to-head data; balanced dual-agonism.
- Tirzepatide — limitations: newer molecule, cardiovascular outcome data still accumulating; single approved route (SC).
Research-use framing
Related reading: Semaglutide monograph, What is Semaglutide, Semaglutide mechanism of action, GLP-1 receptor explained, SUSTAIN-6 and STEP programme.
References10
- 1.
Lau J, Bloch P, Schäffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.. Journal of Medicinal Chemistry. 2015;58(18):7370-7380.
- 2.
Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide.. Frontiers in Endocrinology. 2019;10:155.
- 3.
Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist for glycemic control and weight loss.. Cell Metabolism. 2022;34(9):1234-1247.e9.
- 4.
Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.. New England Journal of Medicine. 2023;389(6):514-526.
- 5.
Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity (STEP 1).. New England Journal of Medicine. 2021;384(11):989-1002.
- 6.
Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).. New England Journal of Medicine. 2016;375(19):1834-1844.
- 7.
Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).. New England Journal of Medicine. 2021;385(6):503-515.
- 8.
Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).. New England Journal of Medicine. 2022;387(3):205-216.
- 9.
Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER).. New England Journal of Medicine. 2016;375(4):311-322.
- 10.
Pratley R, Amod A, Hoff ST, et al.. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4).. Lancet. 2018;394(10192):39-50.
Evidence summary
Research limitations
- SURPASS-2 compared a single Semaglutide dose (1 mg) against three Tirzepatide doses — not a full dose-range comparison.
- Cardiovascular and renal outcome data for Tirzepatide are still accumulating.
- Between-assay potency comparisons of acylated peptides are sensitive to buffer and plasticware.
- What is Semaglutide?
Beginner-friendly research-focused introduction to Semaglutide — a long-acting GLP-1 receptor agonist derived from native GLP-1(7-37).
- Semaglutide Mechanism of Action
Receptor-level explanation of Semaglutide's activity at GLP-1R — Gαs / cAMP / PKA / EPAC2 signalling, β-arrestin recruitment, insulinotropic and glucagonostatic effects, gastric emptying and central appetite modulation.
- Semaglutide FAQ
Comprehensive research-focused FAQ on Semaglutide — identity, receptor pharmacology, structural modifications, pharmacokinetics, laboratory handling, evidence base and regulatory status.
- Semaglutide Pharmacokinetics
Reported pharmacokinetics of Semaglutide — half-life, albumin binding, C18 di-acid acylation, absorption for subcutaneous vs oral formulations, distribution, steady state and research limitations.
- Semaglutide Research Applications
Overview of published Semaglutide research contexts — metabolic, cardiovascular, renal, neuroinflammation/CNS and NAFLD/MASH — with a clear preclinical vs human evidence split.
- Albumin Binding and Half-Life Extension
Reusable mechanism guide explaining how fatty-acid acylation supports reversible non-covalent binding to serum albumin, and how that extends the plasma half-life of GLP-1 peptides.
Research use only
Publication information
- Published
- 2026-10-15
- Updated
- 2026-10-15
- Reviewed
- 2026-10-15
- Version
- 1.0
Revision history
- v1.02026-10-15· Editorial Team
Authority Sprint 2D — initial publication of GLP-1 comparison guides.
Editorial standards
Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.
Conflict of interest
Next scheduled review: 2028-04-15. Our research methodology describes how the review is conducted.